Maa: Euroopan unioni
Kieli: englanti
Lähde: EMA (European Medicines Agency)
memantine hydrochloride
KRKA, d.d.
N06DX01
memantine
Other anti-dementia drugs
Alzheimer Disease
Treatment of patients with moderate to severe Alzheimer’s disease.
Revision: 8
Authorised
2013-04-28
23 B. PACKAGE LEAFLET 24 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT MARIXINO 10 MG FILM-COATED TABLETS memantine hydrochloride READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Marixino is and what it is used for 2. What you need to know before you take Marixino 3. How to take Marixino 4. Possible side effects 5. How to store Marixino 6. Contents of the pack and other information 1. WHAT MARIXINO IS AND WHAT IT IS USED FOR Marixino contains the active substance memantine hydrochloride. It belongs to a group of medicines known as anti-dementia medicines. Memory loss in Alzheimer’s disease is due to a disturbance of message signals in the brain. The brain contains so-called N-methyl-D-aspartate (NMDA)-receptors that are involved in transmitting nerve signals important in learning and memory. Marixino belongs to a group of medicines called NMDA-receptor antagonists. Marixino acts on these NMDA-receptors improving the transmission of nerve signals and the memory. Marixino is used for the treatment of patients with moderate to severe Alzheimer’s disease. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MARIXINO DO NOT TAKE MARIXINO - if you are allergic to memantine or any of the other ingredients of this medicine (listed in section 6). WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Marixino: - if you have a history of epileptic seizures - if you have recently experienced a myocardial infarction (heart attack), or if you are suffering from congestive heart failure or from an unc Lue koko asiakirja
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Marixino 10 mg film-coated tablets Marixino 20 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Marixino 10 mg film-coated tablets Each film-coated tablet contains 10 mg memantine hydrochloride equivalent to 8.31 mg memantine. Marixino 20 mg film-coated tablets Each film-coated tablet contains 20 mg memantine hydrochloride equivalent to 16.62 mg memantine. Excipient with known effect: lactose monohydrate _Marixino 10 mg film-coated tablets_ Each film-coated tablet contains 51.45 mg lactose monohydrate. _Marixino 20 mg film-coated tablets_ Each film-coated tablet contains 102.90 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet Marixino 10 mg film-coated tablets White, oval, biconvex film-coated tablet, scored on one side (tablet length: 12.2–12.9 mm, thickness: 3.5–4.5 mm). The tablet can be divided into equal doses. Marixino 20 mg film-coated tablets White, oval, biconvex film-coated tablet (tablet length: 15.7–16.4 mm, thickness: 4.7–5.7 mm). 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of adult patients with moderate to severe Alzheimer’s disease. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia. Posology Therapy should only be started if a caregiver is available who will regularly monitor the intake of the medicinal product by the patient. Diagnosis should be made according to current guidelines. The tolerance and dosing of memantine should be reassessed on a regular basis, preferably within three 3 months after start of treatment. Thereafter, the clinical benefit of memantine and the patient’s tolerance of treatment should be reassessed on a regular basis according to current clinical guidelines. Maintenance treatment can be continued for as long as a therapeutic benefit is favourable and the patien Lue koko asiakirja